Wave Life Sciences WVE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -53.7%+2.4pp | -56.2%— | —— | —— | —— | |
| Return on assets | -42.1%-0.9pp | -41.3%— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 11.3×+4.8× | 6.5×+4.0× | 2.5×0.0× | 2.6×-0.4× | 3×+0.1× | |
| Quick ratio | 11.3×+4.8× | 6.5×+4.0× | 2.5×0.0× | 2.6×-0.4× | 3×+0.1× | |
| Cash ratio | 10.9×+4.6× | 6.3×+4.0× | 2.3×-0.1× | 2.4×-0.4× | 2.8×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $2.56-16.8% | $3.07+314% | $0.74-12.6% | $0.85-19.6% | $1.06-30.3% | |
| Valuation | ||||||
| Market capitalization | $1.14B+13.0% | $3.16B+171% | $1.17B+9.7% | $1.06B-14.3% | $1.24B-34.3% | |
| Enterprise value | $615.92M-22.3% | $2.57B+160% | $989.1M+12.9% | $875.72M-14.2% | $1.02B-36.6% | |
| Price / book | 2.2×-3.7× | 6.1×-3.3× | 9.4×+1.7× | 7.6×+0.4× | 7.2×-1.8× | |
| Free cash flow yield | -16.2%+1.7pp | -6%+11.0pp | -17%+1.8pp | -18.8%-4.2pp | -14.6%-6.6pp | |
| Earnings yield | -16%— | -6.5%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Wave Life Sciences's ratios come from?
- Every ratio is computed from Wave Life Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
